The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSQN.L Regulatory News (SQN)

  • There is currently no data for SQN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Outcome of KPMG Review & Release of December NAV

31 Mar 2020 13:01

RNS Number : 2488I
SQN Asset Finance Income Fund Ltd
31 March 2020
 

31 March 2020

SQN Asset Finance Income Fund Limited

("the Company")

 

Outcome of the KPMG review of AD Plants valuation

Release of the NAV of the Ordinary Shares for 31st December 2019

 

On 13th February 2020 the Company announced that it had engaged KPMG Ireland ("KPMG") to undertake an independent valuation of six Anaerobic Digestion ("AD") plants ("the AD Plants") as at 31st December 2019 including a review of the valuation model used for those AD assets. The Board sought independent advice as a result of the wide range of valuations, which were notably lower than previously, presented to the Board by the Investment Managers for the 31st December 2019 NAV. KPMG have significant experience in the AD sector having been advisors in connection with the purchase and sale of a number of AD plants, M&A, refinancings and valuations.

 

Whilst the review was taking place, the Company was unable to calculate and release the NAVs for 31st December 2019, 31st January 2020 and 29th February 2020 for the Ordinary Shares. The NAVs for the C Shares for those dates were released as usual as the C Shares do not hold any AD assets.

 

The Board has now received the KPMG report. KPMG provided a range of valuations of the AD Plants prepared on a Fair Value basis of between £64.76m and £73.26m ("the FV Range") as at 31st December 2019. This range is derived from a discounted cash flow model using expert input as well as observed market transactions. The valuations are reflective of the operational capability and contractual positions of the AD Plants as at 31st December 2019, taking account of prudent estimates of cash flow upside where KPMG believe that a willing investor would likely attribute value as part of a competitive acquisition process. A detailed paper and va(D) luation model has been provided to the Company for each AD Plant.

 

KPMG has further stated that should a point value be required, as it is for the calculation of the NAV and for the production of the Company's Interim Financial Statements to 31st December 2019, the mid-point of the FV Range could be considered appropriate ("the FV Mid-Point"). The Board has determined to use the FV Mid-Point and, accordingly, the Fair Value of the Company's investment in AD Plants is £55.33m, resulting in additional expected credit losses on the related credit investments of £73.71m, equivalent to 20.71p per Ordinary Share or 22.20% of the Ordinary Share NAV. This has been calculated taking into account other lenders on three of the AD Plants, the outstanding debt held in the Company's books and the Company's existing IFRS9 Expected Credit Losses.

 

As a result, the unaudited, estimated NAV per Ordinary Share as at 31st December 2019 was 72.57p, representing a decrease of 21.11p per Ordinary Share or 22.53% from 30th November 2019.

 

The Investment Managers believe that there remain opportunities to create value in excess of the FV Range based on a number of factors that are not included in the KPMG Fair Value valuations. These include measures that could add value to each AD Plant if certain enhancements were to be undertaken such as, amongst other things, private wire contracts, heat off-take contracts, digestate contract cost reductions, additional RHI income from heat recovery systems and recoveries from contractor guarantees for faulty work. Based on these assumptions the valuation range is £97.09m to £108.99m. Furthermore, there may be an opportunity to create value beyond this range, in particular if the AD Plants were sold as a portfolio of assets which might attract a valuation premium.

 

The Board believes that using the FV Mid-Point is the most appropriate value to use for the calculation of the Ordinary Shares NAV as there is no assurance that the improvements that might lead to value in excess of the FV Range can be achieved.

 

The Board has also determined that the FV Mid-Point remains appropriate for the calculation of the Ordinary Shares NAVs for 31st January 2020 and 29th February 2020 and the NAVs for those dates will be released shortly.

 

 

 

For further information please contact:

 

SQN Capital Management, LLC

Jeremiah Silkowski jsilkowski@sqncapital.com

Nicola Bird nbird@sqncapital.com

Catherine Halford Riera chalford@sqncapital.com

 

01932 575 888

Winterflood Securities Limited

020 3100 0000

Neil Langford

Chris Mills

 

Buchanan

Charles Ryland

Victoria Hayns

Henry Wilson

 

 

 

020 7466 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCWPUMAWUPUGGG
Date   Source Headline
28th Dec 201611:36 amRNSDirector/PDMR Shareholding
23rd Dec 20161:12 pmRNSDirector/PDMR Shareholding
19th Dec 20167:00 amRNSMonthly NAV and Dividend
8th Dec 20167:00 amRNSResult of Placing, Open Offer and Offer for Subs
6th Dec 20168:00 amRNSResult of EGM
2nd Dec 20163:31 pmRNSHolding(s) in Company
24th Nov 201612:00 pmRNSResult of AGM
16th Nov 201611:00 amRNSHolding(s) in Company
15th Nov 20167:00 amRNSMonthly NAV and Dividend
9th Nov 20167:00 amRNSPlacing, Open Offer and Offer for Subscription
8th Nov 20162:30 pmRNSPublication of a Prospectus
2nd Nov 20164:21 pmRNSHolding(s) in Company
1st Nov 20167:00 amRNSTotal Voting Rights
28th Oct 20167:00 amRNSNotice of AGM
27th Oct 20167:00 amRNSIntention to Raise Capital
26th Oct 20164:32 pmRNSHolding(s) in Company
21st Oct 20167:00 amRNSNAV, Dividend and Update on C Share Conversion
14th Oct 20167:00 amRNSC Share Investment Update
10th Oct 20163:41 pmRNSHolding(s) in Company
21st Sep 20166:00 pmRNSAnnual Financial Report
21st Sep 20167:00 amRNSMonthly NAV and Dividend
15th Sep 201612:06 pmRNSHolding(s) in Company
24th Aug 20164:49 pmRNSHolding(s) in Company
18th Aug 20167:00 amRNSMonthly NAV and Dividend
21st Jul 20167:00 amRNSMonthly NAV and Dividend
21st Jun 20167:00 amRNSMonthly NAV and Dividend
20th Jun 20169:15 amRNSDirector Declaration
23rd May 20167:00 amRNSMonthly NAV and Dividend
10th May 201612:32 pmRNSHolding(s) in Company
21st Apr 20167:00 amRNSMonthly NAV and Dividend
21st Mar 20167:00 amRNSMonthly NAV and Dividend
22nd Feb 20167:00 amRNSMonthly NAV and Dividend
22nd Feb 20167:00 amRNSHalf Yearly Report
28th Jan 20167:00 amRNSDisclosure of Home Member State
27th Jan 20164:55 pmRNSHolding(s) in Company
22nd Jan 20167:00 amRNSMonthly NAV and Dividend
12th Jan 20167:00 amRNSTransactions in a Close Period
22nd Dec 20151:00 pmRNSDirector Declaration
21st Dec 20157:00 amRNSMonthly NAV and Dividend
14th Dec 201512:00 pmRNSHolding(s) in Company
1st Dec 20153:36 pmRNSTotal Voting Rights
30th Nov 201511:20 amRNSHolding(s) in Company
23rd Nov 201510:17 amRNSHolding(s) in Company
20th Nov 20153:00 pmRNSFCA Listing Rules
20th Nov 20157:00 amRNSMonthly NAV and Dividend
19th Nov 20154:08 pmRNSResult of AGM
12th Nov 201511:01 amRNSTotal Voting Rights
9th Nov 201511:07 amRNSDirector/PDMR Shareholding
4th Nov 20157:00 amRNSResult of Placing
21st Oct 20157:00 amRNSMonthly NAV and Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.